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Background: The role of combination ICS/LABA as initial controller therapy in mild, persistent
asthma is uncertain. Therefore, the objective of this study was to compare the efficacy of
initial controller therapy with fluticasone propionate (FP) 100 mg twice daily to the efficacy
of fluticasone propionate/salmeterol xinafoate (FSC) 100/50 mg twice daily in patients with
persistent asthma symptoms while using as-needed SABA alone.
Methods: This randomized, double-blind, parallel-group study was conducted at 45 general
practice and 15 specialist centers. A total of 526 adult patients were randomized to receive
FP or FSC for 24 weeks. The primary efficacy endpoint was change in morning peak expiratory
flow (PEF) from baseline. Secondary efficacy endpoints included symptom- and rescue-free
days; asthma exacerbation rate; asthma-related health-care utilization; and the onset of
effect. Safety was assessed by monitoring adverse events.
Results: Mean morning PEF was significantly greater in the FSC versus the FP group (P < 0.001);
this greater effect was evident as early as the first week of treatment (P < 0.001). The
percentages of symptom-free days and rescue-free days in the FSC group were 7.7%
(PZ 0.009) and 8.4% (PZ 0.001) higher than the FP group, respectively. Trends toward lower
exacerbation-related health care-utilization for FSC versus FP were not statistically significant
and exacerbation rates were not significantly different. The incidence of adverse events was
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Fluticasone propionate alone or with salmeterol in mild asthma 511Conclusions: Treatment with FSC was a more effective initial controller therapy than FP
monotherapy in ICS-naı¨ve patients who had uncontrolled asthma while using as-needed SABA
alone.
ª 2009 Published by Elsevier Ltd.Introduction
Although national and international asthma guidelines
provide evidence-based recommendations on asthma
management in an effort to improve short- and long-term
outcomes for patients with asthma,1e3 achieving asthma
control remains an elusive goal. This is well illustrated in
a recent Personal Practice Assessment Program survey in
which more than 350 Canadian primary-care physicians
were surveyed about the asthma control status of more
than 10,000 treated patients and showed that 59% were
uncontrolled,4 a finding that is consistent with previous
reports.5,6 These uncontrolled patients were 6 times more
likely to have an unscheduled health-care visit, nearly 4
times more likely to seek care in an emergency depart-
ment, and twice as likely to be admitted to hospital for
uncontrolled disease, compared with their controlled
counterparts.
Practice guidelines generally advocate the use of low-
dose inhaled corticosteroids (ICS) as controller mono-
therapy for patients with persistent symptoms while using
as-needed short-acting b2-agonists (SABA) alone.
1 The
addition of long-acting b2-agonists (LABA) to ICS (combi-
nation therapy) has been recommended as a subsequent
controller step for patients inadequately controlled by such
low-dose inhaled corticosteroid monotherapy.7e9 This
recommendation is based on the greater improvements
seen with ICS/LABA combination therapy on asthma
control, asthma exacerbations and airway hyper-
responsiveness compared to ICS therapy alone in studies of
mild to moderate or moderate to severe patients, a subset
of which were steroid-naı¨ve at study entry.8,10e12
It is plausible that earlier combination ICS/LABA treat-
ment might benefit ICS-naı¨ve patients with asthma who are
inadequately controlled with as-needed SABA.1 Unfortu-
nately, most studies assessing whether clinical improve-
ments occur with combination therapy in patients
uncontrolled on SABAs alone have involved patients with
moderate to severe asthma13e16 and there has been limited
investigation to determine if ICS/LABA treatment provides
an incremental clinical benefit over ICS alone in mild
persistent asthma.17 Extrapolating from data gathered in
patients with moderate to severe disease or from patients
currently taking ICS/LABA combination therapy in practice
settings, additional benefits of combination therapy might
not be limited to delay of exacerbations but might include
improved control of day-to-day asthma symptoms,
improved lung function and more rapid achievement of
disease control as compared to inhaled steroid mono-
therapy.18 This hypothesis has been challenged by the
findings of the OPTIMA study. In steroid-naı¨ve patients with
mild asthma, treatment with low-dose budesonide
improved the rate of asthma exacerbations and poorly
controlled asthma days. However, the addition offormoterol to budesonide provided further benefit over
that seen for budesonide alone for lung function but not for
other outcome variables.19 Importantly, patients in the
OPTIMA trial had relatively minimal daily symptoms;
a question remains about the relative treatment effects of
ICS/LABA versus ICS alone in steroid-naı¨ve patients with
a poorer level of asthma control.
In light of the above, the objective of the current study
was to compare the efficacy of initial controller therapy
with fluticasone propionate/salmeterol xinafoate (FSC,
Advair/Seretide) Diskus 50/100 mg BID versus fluticasone
propionate (FP, Flovent/Flixotide) Diskus 100 mg BID for
the management of patients with mild asthma uncontrolled
with SABA alone.Methods
Study design and treatments
This was a randomized, double-blind, multicenter, parallel-
group study conducted at 45 general practice and 15
specialist centers across Canada between October 2002 and
February 2004. The study (Protocol SAS40068) was
approved by the institutional review board of each
participating center, and was conducted in accordance with
the principles of the Declaration of Helsinki. All partici-
pants gave written informed consent.
Male and female patients aged 12 years with a docu-
mented history of asthma treated with SABA only and with
forced expiratory volume in 1 s (FEV1)  80% predicted
were eligible for recruitment to the 2-week run-in period.
Key exclusion criteria were the use of asthma controller
medications in the previous month or systemic corticoste-
roids in the previous 12 weeks; exacerbation requiring
either emergency room treatment in the previous 6 weeks
or hospitalization in the previous 12 weeks; and smoking
history of 10 pack years.
Patients were randomized to treatment if they had any
of the following during the last 7 days of the run-in period:
asthma symptom score 2 on 3 days, disruptions of normal
sleep patterns on 2 occasions, or use of rescue medication
on 4 days. Patients were excluded at this stage if they had
changed asthma medication, suffered a respiratory tract
infection, or required an emergency room visit or hospi-
talization for asthma.
Eligible patients were randomized 1:1 to FSC 50/100 mg
BID or FP 100 mg BID (both administered via Diskus inhaler)
for 24 weeks, assessed at 4-weekly intervals, with a tele-
phone follow-up 2 weeks later. Daily record cards (DRCs)
were used to record peak expiratory flow (PEF), asthma
symptom score (measured on a 0e5 scale; 0 corresponding
to no symptoms and 5 corresponding to symptoms that
prevented work and normal activities); disruptions to sleep
512 P.M. Renzi et al.caused by asthma; rescue medication use; and time missed
from work/school/usual activities. Patients were instruc-
ted to take their study medication in the morning and
evening after their PEF recording. Rescue salbutamol
sulphate HFA aerosol (Ventolin HFA) was provided for
symptomatic relief. Compliance was measured by
recording the number of doses remaining in each inhaler
when returned.
Severe exacerbations were defined as deterioration in
asthma requiring emergency hospital treatment/admission
or according to investigator opinion. A patient was with-
drawn if he or she required hospitalization or more than 3
exacerbations requiring treatment with oral corticoste-
roids. Safety was assessed by monitoring and recording
adverse events (AEs). Health outcomes were assessed by
measuring use of unscheduled asthma-related resources
during the treatment period.Statistical analysis
The sample size calculation was based on the primary
endpoint, the change in mean morning PEF from baseline to
the end of the 24-week treatment period. It was estimated
that approximately 260 patients per arm were needed to
detect a difference of 20 L/min based on an expected
standard deviation (SD) of 70 L/min, (aZ 0.05 and
bZ 0.1). Secondary efficacy endpoints included change
from baseline in mean evening PEF and morning FEV1; the
percentage of symptom- and rescue-free days; asthma
exacerbation rate; and the onset of effect. To validate the
mean morning and evening PEF measured over the entire
treatment period, these were compared to PEF measured
over the last 7 days of treatment. No statistical adjustment
was made for the multiple comparisons of the secondary
analyses.
All efficacy analyses were performed on the intent-to-
treat (ITT) population, comprising all patients who took 1
dose of randomized study medication and provided
a primary efficacy evaluation of their treatment. Changes
from baseline in mean PEF and mean FEV1, as well as
percentage of symptom-free 24-h days and rescue-free
24-h days, were analyzed using ANCOVA, adjusting for
baseline values, study center, age, sex and height. Changes
in percentage of symptom-free 24-h days and rescue-free
24-h days for various time intervals were also summarized,
categorized (0 to <15%; 15 to <30%; 30 to <45%; 45 to
<60%; and 60 to100%) and compared across treatment
groups using a proportional odds model, adjusting for
baseline, study center, age and sex. Exacerbation rate was
analyzed using the maximum likelihood-based analysis
assuming a Poisson distribution with time on treatment as
an offset variable. The model was adjusted for center, age
and sex.
Assessment of efficacy variables during the last 7 days of
treatment used a last observation carried forward approach
to impute missing efficacy assessments. For patients who
withdrew from the study prematurely, all available data up
to the time of withdrawal were included in the analysis.
The safety analyses were performed on all randomized
patients who received 1 dose of randomized study
medication.Results
Patient disposition and baseline characteristics
Of the 664 patients who completed a screening visit for this
study, 526 patients were randomized to 1 of the 2 treat-
ment groups (Fig. 1). Most of the demographic character-
istics were similar in both treatment groups, except for
a slight difference in smoking history. Pulmonary function
and diary card data at baseline were similar at baseline
(Table I). Patients in both groups had a lung function of
approximately 93% of the predicted FEV1.
Changes in lung function
After the 24-week treatment period the mean morning PEF
was significantly greater in the FSC group than in the FP
group (15.2 L/min, 95% CI 8.0, 22.4; P < 0.001; Fig. 2); this
greater level of improvement with FSC over FP was evident
as early as the first week of treatment (14.4 L/min, 95% CI
8.3, 20.1; P < 0.001). Similarly, a significantly greater
change in mean morning PEF from baseline in the FSC
group than in the FP group was also observed in the last
7 days of treatment (15 L/min, 95% CI 6.3, 23.6;
P < 0.001). Compared with the FP group, the FSC group
demonstrated a significantly greater change in mean
evening PEF over the 24-week treatment period (15 L/min,
95% CI 8.2, 21.9; P < 0.001; Fig. 2) and during the last
7 days of treatment (15 L/min, 95% CI 6.5, 23.4;
P < 0.001). The change in morning clinic FEV1 from base-
line to week 24 was greater in FSC-treated patients than in
FP-treated patients (0.14  0.03 versus 0.08  0.02 L,
PZ 0.011).
Changes in other markers of asthma control
Patients randomized to FSC reported a significantly higher
mean percentage of symptom-free days than those
randomized to FP (7.7, 95% CI 1.9, 13.5; PZ 0.009, Fig. 2).
Similarly, patients randomized to FSC reported a signifi-
cantly higher mean percentage of rescue-free days than
those randomized to FP (8.4, 95% CI 3.1, 13.5; PZ 0.001,
Fig. 2). This translated into a statistically significant greater
reduction in mean daily rescue use from baseline in the FSC
compared to the FP group (1.2  0.04 versus 1.0  0.04
fewer rescue inhalations, PZ 0.028). The treatment
difference between FSC and FP over all 4-week intervals
examined was statistically significant in favor of FSC for
symptom- and rescue-free days (for both P < 0.05; Fig. 2).
In addition, at each consecutive 4-week period, a signifi-
cantly greater proportion of patients in the FSC group than
in the FP group had 60% symptom- and rescue-free days.
In addition, a similar number of asthma-related severe
exacerbations (3 per group, 6%) occurred in the 2 treatment
groups.
Asthma-related resource utilization
Fewer patients randomized to FSC than FP used unscheduled
asthma-relatedhealth resources (38versus59)which included
270 subjects randomized 
to FP 100 µg twice-daily
and received ≥1 dose 
Safety population 
262 subjects randomized to 
FSC 50/100 µg twice-daily
and received ≥1 dose 
Safety population 
253 subjects received ≥1
dose, and provided an 
evaluation, of randomized 
medication 
ITT population 
263 subjects received ≥1
dose, and provided an 
evaluation, of randomized 
medication 
ITT population 
39 withdrawals prior 
to study completion 
Nine withdrawals prior 
to provision of an 
evaluation of 
randomized medication  
44 withdrawals prior 
to study completion 
209 study completers 
53 withdrawals in FSC 50/100 µg 
twice-daily group between 
randomization and completion: 
– 6 AEs 
– 13 consent withdrawn 
– 18 lost to follow-up 
– 4 protocol violations 
– 2 failed to fulfill entry criteria 
– 1 lack of efficacy 
– 9 other reasons 
46 withdrawals in FP 100 µg twice-
daily group between randomization 
and completion: 
– 11 AEs 
– 7 consent withdrawn 
– 16 lost to follow-up 
– 5 protocol violations 
– 1 failed to fulfill entry criteria 
– 1 lack of efficacy 
– 5 other reasons 
132 withdrawals prior to randomization 
-  100 did not meet inclusion criteria 
-  22 had adverse event 
-  10 withdrew consent 
-  17 lost to follow up 
-  1 protocol violation 
-  2 asthma exacerbation 
664 subjects screened 
224 study completers 
Seven withdrawals prior to 
provision of an evaluation 
of randomized medication 
Figure 1 Patient disposition.
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versus 7), office/practice visit (14 versus 19), outpatient clinic
visit (1 versus 6) and emergency room visit (3 versus 3),
respectively. These trends in use of health resources between
groups were not statistically significant. The average compli-
ance to the study drug according to patient daily diary card
records was approximately 90% for both treatment groups.
Safety assessments
Overall, the incidence of AEs was similar in both treatment
groups. The incidence of study drug-related AEs was low;
no single drug-related event occurred in more than 2% of
patients in either group. The incidence of serious AEs wasalso similar across treatments, 3 (1%) occurred in the FSC
and 4 (1%) in the FP group; none of the serious AEs were
considered by the investigator to be related to treatment
with the study medication. Withdrawal from study due to
an AE was 5 (2%) in FSC and 9 (3%) in the FP group. One
patient in the FP group died during the study from cardiac
arrest that was not considered related to study drug.
Discussion
This study shows that in symptomatic patients with appar-
ently mild asthma, initial controller therapy with a low-dose
ICS/LABA combination provides more relief of symptoms and
improved lung function as compared to a low-dose ICS alone.
Table 1 Demographic and baseline characteristics.
Assigned treatment
FSC (nZ 253) FP (nZ 263)
Sex, n (%)
Female 162 (64) 169 (64)
Male 91 (36) 94 (36)
Age (mean  SE; years), (range) 34.8  0.90, (12e76) 34.3  0.88, (12e77)
Racial/ethnic origin, n (%)
Caucasian 225 (89) 236 (90)
Black 4 (2) 5 (2)
Asian 22 (9) 18 (7)
Other 2 (<1) 4 (2)
Height (mean  SE; cm) 166.9  0.61 165.7  0.61
BMI (mean  SE; kg/m2) 27.81  0.40 28.47  0.43
Weight (mean  SE; kg) 77.7  1.23 78.4  1.29
Smoking history
Current, n (%) 23 (9) 40 (15)
Former, n (%) 82 (32) 54 (21)
Pack years (mean  SD) 4.20  3.22 (0.31) 4.05  2.98 (0.31)
Clinic lung function (mean  SE)
% Predicted normal FEV1 92.8  0.70 92.7  0.64
Pre-bronchodilator FEV1 (L) 3.03  0.04 3.00  0.05
Post-bronchodilator FEV1 (L) 3.25  0.05b 3.18  0.05c
% Reversibility of FEV1 6.92  0.41b 6.39  0.43c
DRC (mean  SE)
Morning PEF (L/min) 395.3  6.43 392.5  6.36e
Evening PEF, L/min 406.3  6.67d 402.5  6.58e
Daily symptom scorea 1.70  0.79 (0.05) 1.80  0.83 (0.05)c
% Symptom-free 24-h days 11.1  19.7 (1.24) 10.0  18.1 (1.12)c
Daily use of rescue 1.70  1.41 (0.09)d 1.60  1.31 (0.08)f
% Rescue-free days 23.3  26.9 (1.69)d 23.8  29.5 (1.82)f
DRC, daily record card; FEV1, forced expiratory volume in 1 s; FP, fluticasone propionate; ITT, intent to treat; PEF, peak expiratory flow;
SD, standard deviation; FSC, fluticasone propionate/salmeterol combination.
a Symptom score based on a 6-point scale where 0Z no symptoms and 5Z symptoms that prevented work and normal activities
b nZ 251
c nZ 260
d nZ 252
e nZ 262
f nZ 261
514 P.M. Renzi et al.Moreover, the combination therapy achieves these improved
outcomes more rapidly than ICS monotherapy.
Although previous studies have shown combination
therapy to be significantly better than inhaled corticoste-
roids alone in the therapy of moderate to severe asthma,7e9
little information is available on whether combination
therapy is better than inhaled corticosteroids alone in ICS-
naı¨ve patients with apparently mild asthma and normal or
nearly normal spirometry. In our study we enrolled patients
with an FEV1 > 80% who were receiving only SABAs as
needed and were considered by their caregivers as having
mild disease. Our findings reinforce previous findings of the
insensitivity of FEV1 measurement in the assessment of
asthma20,21 and support current guideline recommenda-
tions that asthma control be evaluated by a composite
index of symptom-based and lung function assessments.
Although traditionally in guidelines the choice of
therapy depended primarily on severity assessment,1e3 the
correlation between severity and the patient’s true overall
health status is poor.6,13,22e25 Patient severity status canvary over time and it is not accurately characterized by
a single clinical measure.1 Often definitions are imprecise
and subjective, and when assessing symptoms emphasis is
often inappropriately placed on individual measure-
ments.26 As highlighted by Miller et al., often there is a lack
of agreement between different methods for assessing
asthma severity such as NAEPP-based, GINA-based and
physician-assessed.27 Given these limitations, current
guidelines now stress the importance of assessing asthma
control in parallel to severity. Control assessment often
reveals suboptimal treatment outcomes. In a recent survey
reported by Chapman et al.,4 primary-care physicians
significantly overestimated control among their patients,
labeling only 42% as uncontrolled. In this survey, physicians
were discordant with guideline classification of control in
31% of uncontrolled patients, 13% of well-controlled
patients and 2% of totally controlled patients. Importantly,
physicians were most commonly discordant with guideline
criteria when patients showed lack of control in terms of
only one parameter, most often when patients were
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Figure 2 Mean change in morning PEF, evening PEF, % symptom-free 24-h periods, % rescue-free 24-h periods.
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consistent with other reports showing the overuse of rescue
medication by patients in an attempt to control their
asthma.5,6 Despite the availability of effective anti-
inflammatory treatments and management guidelines, this
survey also found that 41% of the 2071 patients only using
a rescue medication for their asthma were poorly
controlled, a disappointingly similar percentage to previous
findings.5,6 Although ICS monotherapy as maintenance
treatment was commonly recommended for uncontrolled
patients (52%), no change in treatment was made forw11%
of these patients.
This study also highlights the symptom burden and risk of
uncontrolled asthma in patients being treated with only
a rescue medication; the average use of SABA at screening
was 1.7 puffs/day and patients reported only 23% rescue-
free days. Another survey reported that 97% of patients,
and about 90% of their physicians, believed that patients’
symptoms were controlled, whereas only 47% of patients
met symptom-based guideline criteria for controlled
disease.5 This high frequency of suboptimal asthma control
is of concern since it increases a patient’s risk for hospi-
talization, systemic corticosteroid treatment and other
urgent care for asthma.4,28
In addition to objective measures of efficacy in the
current study, improvements in subjective measures of
symptom control was also seen with treatment with
a significantly greater benefit in FSC-treated patients.
There was approximately an 8% greater improvement with
FSC compared with FP in the percentage of both symptom-
free and rescue-free days. This suggests that, compared
with FP alone, FSC increases the number of days withoutsymptoms or the need for rescue medication by 1 additional
month over the course of a year. These results build on
previous studies that have shown a significant benefit with
regular ICS treatment in mild persistent asthma17 and on
studies that have shown the addition of salmeterol leads to
significant improvement in lung function, symptom-free
days, rescue use and symptom score in comparison to FP
alone.14,15,29
Our results are somewhat in contrast to those reported
in the OPTIMA trial.19 The incremental benefit observed
with the addition of a LABA to ICS therapy in the current
study may be explained by greater level of baseline
frequency of daily symptoms and rescue use in the
patients. However, indirect comparison of the results of
this study to those of the OPTIMA study should be made
cautiously given the number of differences between the
trials, including differences in endpoints on which the
studies were powered, treatment duration, ICS potency of
the medications studied and patient characteristics (e.g.
baseline asthma control).
The benefit-to-risk profile for ICS/LABA combination
therapy is favorable in patients when used according to
current treatment guidelines and standards of care which
mandate concurrent ICS therapy. Importantly, even
patients thought to have mild asthma are at risk of severe,
and even fatal, asthma exacerbations.30 Therefore, opti-
mized therapy tailored to appropriate patients will
continue to offer a favorable benefit-to-risk profile for the
use of combination therapy. Taken together, these data
suggest that a subset of steroid-naı¨ve patients at risk for
exacerbations and with a high level of asthma impairment
may benefit from ICS/LABA treatment while the majority of
516 P.M. Renzi et al.asthmatics will be well managed on an optimal dose of ICS
alone.
Our patients with putatively mild, steroid-naı¨ve disease
had greater day-to-day freedom from symptoms and
asthma disability on combination therapy but did not
appear to have fewer exacerbations as diagnosed by their
physicians. Strong but non-significant trends were seen
towards decreased health-care utilization in the combi-
nation-treated patients though the study was not powered
to assess differences in health care-utilization between
treatment groups. This finding, along with the significant
improvement in lung function, symptoms and rescue use,
is consistent with recent observations demonstrating the
association between lack of day-to-day symptom control
of asthma and excess health-care utilization.31 Asthma-
related quality of life was not measured in this study which
is a limitation of the current, as well as other large
treatment trials in mild asthma. In a report by Bateman
and colleagues, improvements in asthma control corre-
lated with improvement in asthma-related quality of
life.11 In contrast, Boushey and colleagues evaluated the
efficacy of intermittent short-course corticosteroid
treatment guided by a symptom-based action plan alone
or in addition to daily treatment with either inhaled
budesonide or oral zafirlukast for 1 year.32 The results of
the IMPACT study showed that daily budesonide therapy
produced significantly greater improvements in lung
function, the percentage of eosinophils in sputum,
exhaled nitric oxide, scores for asthma control, and the
number of symptom-free days, but not in post-broncho-
dilator FEV1 (PZ 0.29) or in the asthma quality of life
(PZ 0.18).32 The differences in the relationship between
markers of asthma control and quality of life observed in
these 2 studies likely is influenced by the level of disease
severity.
In summary, steroid-naı¨ve patients with asthma who
have persistent symptoms without controller therapy ach-
ieve better symptom control, better lung function and do so
more rapidly when treated with low-dose ICS/LABA than
low-dose ICS alone. Although the majority of the mild
asthmatic population may be well managed on ICS alone,
there may be a segment of the patient population who are
labeled as having mild asthma that could benefit from ICS/
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